Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

264.74
-2.8300-1.06%
Post-market: 264.740.00000.00%18:29 EDT
Volume:6.34M
Turnover:1.68B
Market Cap:637.84B
PE:30.66
High:268.48
Open:267.91
Low:264.51
Close:267.57
52wk High:281.07
52wk Low:182.94
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.06
T/O Rate:0.26%
Dividend:5.24
Dividend Rate:1.98%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.51
PE(LYR):23.99

Loading ...

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
1 hour ago

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
1 hour ago

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Yesterday

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Yesterday

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Yesterday

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Yesterday

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Yesterday

Johnson & Johnson's Icotyde Seen Reaching $4.5 Billion in Peak Psoriasis Sales, BofA Says

MT Newswires Live
·
Yesterday

Update: BofA Securities Raises Price Target on Johnson & Johnson to $278 From $263, Keeps Neutral Rating

MT Newswires Live
·
Sep 29

Johnson & Johnson is Maintained at Neutral by JP Morgan

Dow Jones
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Johnson & Johnson price target raised to $278 from $263 at BofA

TIPRANKS
·
Sep 29

JPMorgan Adjusts Price Target on Johnson & Johnson to $285 From $270, Keeps Neutral Rating

MT Newswires Live
·
Sep 29

US Research Roundup-Acuity, Dell Technologies, Nike

Reuters
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29